BNGO BIONANO GENOMICS INC

Bionano Genomics to Report Third Quarter 2022 Financial Results and Host a Conference Call and Webcast on November 3, 2022

Bionano Genomics to Report Third Quarter 2022 Financial Results and Host a Conference Call and Webcast on November 3, 2022

SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced that it will host a conference call and live webcast on Thursday, November 3, 2022 at 4:30 p.m. Eastern Time to report financial results for the third quarter 2022 and to highlight recent corporate progress.

Conference Call & Webcast Details
Date:Thursday, November 3, 2022
Time:4:30 p.m. Eastern Time
Live Call:Toll Free: 1-877-502-9276

Toll/International: 1-720-543-0302
Live Webcast:-server.com/mmc/p/cz29oo8z



A replay of the conference call and webcast will be archived on Bionano’s investor relations website at  for at least 30 days.

About Bionano Genomics

Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view.

For more information, visit ,  or 

CONTACTS

Company Contact:

Erik Holmlin, CEO

Bionano Genomics, Inc.

+1 (858) 888-7610

Investor Relations:

Amy Conrad

Juniper Point

+1 (858) 366-3243



EN
27/10/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BIONANO GENOMICS INC

 PRESS RELEASE

Bionano Reports First Quarter 2025 Results and Highlights Recent Busin...

Bionano Reports First Quarter 2025 Results and Highlights Recent Business Progress Conference call today, May 14, 2025, at 4:30 PM ET SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the first quarter ended March 31, 2025. “The first quarter of 2025 represents the first full quarter of execution after shifting strategy towards a focus on our base of routine users of optical genome mapping (OGM) and VIA™ software as the primary drivers of our revenue and gross profit.   We are pleased to see consistent utilization of ...

 PRESS RELEASE

Bionano to Report First Quarter 2025 Financial Results and Host a Conf...

Bionano to Report First Quarter 2025 Financial Results and Host a Conference Call Webcast on May 14, 2025 SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 14, 2025, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2025 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Wednesday, May 14th, 2025Time:4:30 p.m. ETParticipant Link:Webcast Link: Participants may access a live webcast of the call on the Investors page...

 PRESS RELEASE

Bionano Announces Publication Showing OGM can Provide an Accurate and ...

Bionano Announces Publication Showing OGM can Provide an Accurate and Cost-Effective Solution for Sizing Large Repeat Expansions in Constitutional Genetic Disease SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a peer-reviewed publication in Genome Research demonstrating that optical genome Mapping (OGM) can be an accurate, cost-effective method for detecting and sizing large repeat expansions, which are a class of structural variation (SV) linked to as many as 40 genetic disorders. Led by Alexander Hoischen and researchers at Radboud Un...

 PRESS RELEASE

Bionano Announces French Publication of an Effective Method for Analys...

Bionano Announces French Publication of an Effective Method for Analysis of Multiple Myeloma by OGM SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a study published in The Journal of Molecular Diagnostics that describes a method for analysis of multiple myeloma (MM) by optical genome mapping (OGM). MM is one of the most common blood cancers, or hematologic malignancies, and is understood to be a difficult sample to analyze using traditional cytogenetics. Direct analysis of MM samples, by methods such as FISH or OGM, can be problematic b...

 PRESS RELEASE

Bionano Reports Fourth Quarter and Full-Year 2024 Results and Provides...

Bionano Reports Fourth Quarter and Full-Year 2024 Results and Provides Revenue Outlook for 2025 Conference call today, March 31, 2025 at 4:30 PM ET SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2024 and revenue outlook for 2025. “2024 has been an important year for Bionano. Despite a challenging external environment with shrinking capital budgets, financial uncertainty for our customers and difficult equity capital markets, we have continued serving our missi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch